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Contraception for HIV-Infected Adolescents
Athena P. Kourtis, MD, PhD, MPH, FAAP, Ayesha Mirza, MD, FAAP, and COMMITTEE ON 
PEDIATRIC AIDS
Abstract
Access to high-quality reproductive health care is important for adolescents and young adults with 
HIV infection to prevent unintended pregnancies, sexually transmitted infections, and secondary 
transmission of HIV to partners and children. As perinatally HIV-infected children mature into 
adolescence and adulthood and new HIV infections among adolescentsand young adults continue 
to occur in the United States, medical providers taking care of such individuals often face issues 
related to sexual and reproductive health. Challenges including drug interactions between several 
hormonal methods and antiretroviral agents make decisions regarding contraceptive options more 
complex for these adolescents. Dual protection, defined as the use of an effective contraceptive 
along with condoms, should be central to ongoing discussions with HIV-infected young women 
and couples wishing to avoid pregnancy. Last, reproductive health discussions need to be 
integrated with discussions on HIV care, because a reduction in plasma HIV viral load below the 
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level of detection (an “undetectable viral load”) is essential for the individual’s health as well as 
for a reduction in HIV transmission to partners and children.
INTRODUCTION
The American Academy of Pediatrics (AAP) recommends that pediatricians develop a 
working knowledge of existing contraceptive methods for adolescents and has recently 
published a clinical report to address this issue.1 Because the evidence base for 
contraception for HIV-infected adolescents has recently expanded, the goal of this clinical 
report is to provide a description and rationale for best practices in counseling and 
administering contraception for adolescents with HIV infection.
HIV type 1–infected adolescents represent an important subgroup within the adolescent 
population. The availability of combination antiretroviral therapy (cART) in the United 
States has led to increasing numbers of children who acquired HIV infection through 
mother-to-child transmission who survive into adolescence and young adulthood. In 
addition, there is also a growing population of horizontally HIV-infected youth. 
Reproductive health education for pediatric patients as well as their health care providers 
represents an important and unmet need in this vulnerable population. Pediatricians 
providing care for adolescents with HIV infection can help them make informed choices by 
addressing their contraceptive needs. The AAP recently published a clinical report and 
accompanying technical report entitled “Contraception for Adolescents.”1 The American 
College of Obstetricians and Gynecologists has also issued an opinion statement 
acknowledging that adolescents who are HIV infected should receive sexual and 
reproductive health counseling and care.2 The intent of this clinical report is to address 
specific considerations and guidance related to contraceptive options available for HIV-
infected adolescents.
HIV-INFECTED ADOLESCENTS IN THE UNITED STATES
At the end of 2012, there were an estimated 10 832 people in the United States and 6 
dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the 
Republic of Palau, and the US Virgin Islands) living with perinatally acquired HIV infection.
3
 In 2010, young people aged 13 to 24 years represented 17% of the US population but 
accounted for an estimated 26% of all new (47 500) HIV infections.4 This number 
represented the second largest percentage of new infections in 2010 (the largest group being 
among those aged 25–34 years [31%]).5
Although the majority of new HIV infections among youth occur among gay and bisexual 
males, female youth in the United States continue to remain vulnerable, with certain ethnic 
groups at higher risk than others. In 2010, black youth accounted for an estimated 57% of all 
new HIV infections in youth in the United States, followed by Hispanic/Latino (20%) and 
white (20%) youth (both male and female).6 Available data show that a majority of 
individuals 15 to 24 years of age in the United States do not perceive that they are at risk of 
acquiring HIV infection and thus are unlikely to take measures to prevent themselves from 
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contracting HIV. Data also show that more than 60% of HIV-infected youth in the United 
States do not know that they are infected.7
As they age, HIV-infected adolescents are more likely to engage in sexual activity, similar to 
uninfected youth populations.8 According to the 2013 Youth Risk Behavior Surveillance 
conducted by the Centers for Disease Control and Prevention (CDC) among students 
nationwide in grades 9 through 12, 48.6% of students reported ever having sexual 
intercourse, with 34% nationwide reporting sexual activity within the 3 months before the 
survey and 5.6% of students nationwide reporting having had sexual intercourse before the 
age of 13 years.9 Among currently sexually active students, 13.7% reported that neither they 
nor their partner had used any method to prevent pregnancy during the last sexual 
intercourse.9 HIV-infected youth can likewise engage in high-risk sexual behaviors, and high 
rates of unintended pregnancy have been documented in that group.8, 10, 11 These statistics 
underscore the importance of reproductive counseling in HIV-infected youth.
Approximately 280 000 HIV-infected women and an estimated 140 000 serodiscordant 
couples live in the United States, many of whom desire children.12 Data from a multisite 
US-based cross-sectional study indicate that there is limited discussion of preconception 
issues between HIV care providers and their patients.12, 13 When such discussions do occur, 
the majority are initiated by patients. Other studies also support this finding.14, 15 The 
routine provision of preconception care and counseling for these individuals is a critical 
need and represents an ongoing challenge. Available data support the fact that unintended 
pregnancies in this population continue to occur.11 The estimated number of women with 
HIV giving birth in the United States increased from 6075 to 6422 births in 2000 to 8650 to 
8900 in 200616 (a 30% increase). Access to medical care and discussion of fertility 
intentions may aid in decreasing the risk of an unplanned pregnancy in this population.12
REPRODUCTIVE HEALTH ISSUES SPECIFIC TO HIV-INFECTED 
ADOLESCENTS
Multiple demographic, psychological, sexual, medical, and relationship- based factors play a 
role in the reproductive decision-making of HIV-infected adolescents and young adults.12–15 
Data suggest that discussions with HIV-infected adolescents about reproductive health led 
by clinical care providers may not focus as much on family planning but rather on the 
prevention of sexually transmitted infections (STIs).17, 18 Discussions about pregnancy 
prevention may have insufficient content related to pregnancy planning in youth as well as in 
older women.19 These findings may reflect general discomfort among pediatric health care 
providers when addressing issues related to sexuality in adolescent patients and concern for 
potential drug interactions between certain antiretroviral drugs and hormonal contraception.
The physician-patient relationship also affects reproductive decision-making. Adolescents 
with chronic medical conditions are faced with many challenges as they transition from 
pediatric to adult care, including the loss of a long-standing physician-patient relationship.
20, 21
 The medical home may represent the only stable environment some of these 
adolescents have ever known.22 Once the transition in care from a pediatric to an adult 
provider occurs, perinatally HIV-infected adolescents, in particular, may have difficulty 
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expressing their medical needs, particularly those related to sexual and reproductive health. 
In addition, both perinatally and horizontally HIV-infected youth may experience 
neurocognitive deficits.23, 24 This situation can not only make the transition more difficult 
but also may present ongoing challenges for both retention in care and adherence to life-
saving cART. Impairment in cognitive ability and reasoning may also present a major barrier 
to complicated discussions about reproductive health and contraceptive counseling.
The integration of family planning services within HIV treatment, care, and prevention 
programs has resulted in an increase in contraceptive use.25–27 The integration of services is 
an as-yet underutilized strategy that holds promise, particularly because multiple 
appointments with different providers pose another barrier to receiving appropriate care. 
Providers report systemic barriers to providing sexual and reproductive health education, 
such as overbooked clinics and large patient loads, which limit the length of one-on-one time 
with patients. In some cases, lack of adequate training on how to effectively provide sexual 
and reproductive health education and discuss these topics with minors presents an 
additional barrier.18 The use of reproductive life planning tools, such as those available on 
the CDC Web site, may aid providers as they approach these topics with their adolescent 
patients.28
CONFIDENTIALITY AND CONSENT: STATE LAWS
Laws in all 50 states and the District of Columbia allow minors to consent to testing and 
treatment of STIs. Some states allow, but do not require, a physician to inform a minor’s 
parents that he or she is seeking or receiving STI services when the physician deems it in the 
minor’s best interests. Iowa is the only state that requires that parents be notified if their 
child tests positive for HIV infection. Laws in 26 states and the District of Columbia 
explicitly give minors the authority to consent to contraceptive services. Twenty states allow 
only certain categories of minors to consent to contraceptive services, and 4 states have no 
relevant policy or case law.29, 30 Improved access to contraceptive health care with fewer 
restrictions to family planning reduces unplanned pregnancies and teen births. For example, 
states with policies that expand access to family planning services for adolescents have been 
associated with lower teen birth rates, at least for some teenagers.31
Familiarity with national and state laws regarding contraceptive treatment of minors is 
important to provide quality health care to adolescents. Maintaining confidentiality within 
the limitations permitted by law is paramount to patient trust and the likelihood that an 
adolescent will return for appropriate guidance and care. Confidentiality is particularly 
important when sexual behaviors are discussed and may be a major factor in adolescents’ 
decisions to disclose such behaviors to their health care providers and, in turn, use 
appropriate health services. Because adolescents are often covered by their parents’ health 
insurance, unintended disclosure of health services to parents may further complicate 
confidentiality. It is important to explain to adolescents when prescribing contraceptive 
agents that there is a potential for unintended disclosure to parents through health plan 
communications. The AAP recommends that pediatricians put sexuality education into a 
lifelong perspective and actively encourage parents to discuss sexuality and contraception 
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consistent with the family’s attitudes, values, beliefs, and circumstances beginning early in 
the child’s life.32
Physicians who provide care for adolescent minors have an ethical duty to promote 
autonomy and advocate for patients to be involved in medical decision-making that affects 
their care, including reproductive health. However, they also have a responsibility to 
recognize when the decision-making capacity of the individual minor may compromise such 
decisions and when decisions are not in the best interest of the patient. Recognizing that 
situations vary, physicians generally should encourage parental involvement and should try 
to correct misconceptions that the minor may have about the consequences of parental 
involvement. The Society for Adolescent Health and Medicine recommends that physicians 
promote effective communication between adolescents and their parents,33 a position that is 
endorsed by the AAP and the American Medical Association.32, 34
METHODS OF CONTRACEPTION
Several resources provide indications and specific practice recommendations for the use of 
particular contraceptive options in HIV-infected females.1, 2, 35 Detailed guidance about the 
use of various contraceptive methods in women with medical conditions, including HIV 
infection, is found in the US Medical Eligibility Criteria for Contraceptive Use.35 Even 
though HIV infection alone does not preclude the use of any hormonal contraceptive 
method,35 medical conditions and medications used in HIV-infected adolescents may 
influence contraceptive choices.
This report is based on the AAP technical report on contraception for adolescents1 but 
focuses on the appropriateness and considerations of each contraceptive method for HIV-
infected adolescents. As in the previous report, contraceptive methods are presented in 
general order of effectiveness, starting with the most effective reversible methods, the long-
acting reversible contraceptive (LARC) methods (contraceptive implants and intrauterine 
devices [IUDs]). LARC methods usually are ideal contraceptive methods for the adolescent 
population, because they are user-independent options that eliminate the need for regular 
adherence for effectiveness. In addition, many HIV-infected adolescents are challenged by 
daily adherence to cART, so adding an additional medication to which they need to adhere 
may be undesirable. Hormonal contraceptive methods do not protect against STIs; a barrier 
method, such as a condom, is recommended for concurrent protection against STIs. Dual 
method use—the use of a condom in conjunction with a highly effective contraceptive 
method—should be encouraged for adolescents,1 because the former can prevent 
transmission of HIV and other STIs to sexual partners. Recommending dual protection use 
should be a central component of reproductive health counseling for HIV-infected 
adolescents.
Progestin Implants
Implants are a highly effective user- and coitus-independent contraceptive method.1 The 
progestin implant Nexplanon (Merck, Whitehouse Station, NJ) consists of a single rod 
containing etonogestrel, the active metabolite of the progestin desogestrel. Implants have a 
failure rate of less than 1%, a Food and Drug Administration–approved duration of action of 
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3 years, and very low complication rates.36 In addition, there is evidence that the 
effectiveness of the implant is unchanged at 4 years of use.37 Studies in adolescents have 
shown that progestin implants are more effective than shorter-acting methods in preventing 
unintended pregnancy,38 primarily because they have very low adherence requirements and 
their typical-use effectiveness approximates perfect-use effectiveness. Changes in menstrual 
bleeding patterns are the most common side effect and the principal reason for method 
discontinuation.39 Data are scant on the effect of progestin implants on bone mineral density.
40, 41
The efficacy of progestin implants may be impaired by hepatic enzyme–inducing drugs that 
act on the cytochrome P450 pathway. Implants, in particular, are potentially more vulnerable 
to the effect of these inducers than other progestin methods, such as injectable 
contraceptives, because hormonal levels are closer to the lowest therapeutic blood 
concentration needed for contraceptive efficacy. Emerging evidence indicates reduced 
levonorgestrel concentrations in women who use levonorgestrel implants and receive 
efavirenz-containing antiretroviral therapy; contraceptive failures have been described in 
such women.42–47 It should be noted that levonorgestrel implants are not available in the 
United States but are available in several other parts of the world. Several case reports and a 
pharmacokinetics study also suggest that efavirenz48 may decrease the efficacy of 
etonogestrel implants (eg, Nexplanon), although additional data are needed.47, 49 Failure of 
the etonogestrel implant was reported in 2 patients receiving efavirenz-based therapy.50 
Prospectively collected data are not yet available to accurately quantify the interaction of 
efavirenz with progestin implants, to note the time of contraceptive failure, and to 
comparatively evaluate against other contraceptive options for HIV-infected women. Data on 
adolescents specifically are not available. Initial concerns about a possible pharmacokinetic 
interaction of levonorgestrel with nevirapine have not been confirmed by subsequent studies.
45
 The National Institutes of Health (NIH) guidance is to use an alternative or additional 
contraceptive method when efavirenz, nevirapine, or most protease inhibitors (PIs) are 
administered to HIV-infected individuals.51, 52 The CDC and the World Health Organization 
(WHO) state that the benefits of using progestin implants outweigh any risks with 
concomitant administration of an antiretroviral agent in HIV-infected women.35, 53
Intrauterine Devices
IUDs are another type of LARC. Four IUDs currently are approved in the United States: a 
copper-containing IUD (copper T380-A; ParaGard; Teva North America, North Wales, PA) 
and 3 levonorgestrel-releasing IUDs (52 mg levonorgestrel; Mirena; Berlax, Montville, NJ; 
52 mg levonorgestrel; Liletta; Actavis, San Francisco, CA; and 13.5 mg levonorgestrel; 
Skyla; Bayer HealthCare Pharmaceuticals, Wayne, NJ). They are appropriate for adolescents 
and are generally safe and effective methods of contraception with a failure rate of less than 
1%.54, 55 The 13.5-mg
levonorgestrel IUD is approved for 3 years,56 and the 52-mg levonorgestrel IUD, depending 
on formulation, is approved for 3 years (Liletta) or 5 years (Mirena), although data for 
Mirena suggest that it remains effective for up to 7 years.57 The copper IUD is approved for 
10 years, but data support its use for 12 years.58 Women will continue to have regular 
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menstrual cycles with the copper IUD; however, these cycles may be heavier with more 
cramping initially. With the levonorgestrel IUD, menses will become more irregular; 
however, overall bleeding will be less, with many women experiencing amenorrhea. 
Individuals with painful menses may have significant improvement of their symptoms with 
the levonorgestrel IUD.54
Despite earlier concerns, IUDs are now considered safe for nulliparous adolescents,1 
because they do not cause tubal infertility in nulliparous women.35, 59 There is a small risk 
of pelvic infection after insertion, but this increased risk does not extend beyond the first 21 
days after insertion.60, 61 Although an ongoing active STI or other pelvic infection is a 
contraindication to IUD placement, an IUD may be inserted in an asymptomatic adolescent 
at high risk of an STI with screening on the day of insertion. The treatment of any new STI 
can be subsequently provided without IUD removal.1, 62 A recent systematic review found 
an overall low incidence of pelvic inflammatory disease among women with HIV who use 
IUDs and no differences in infectious complications when comparing IUD complication 
rates by HIV disease stage; however, the evidence was limited and of fair to poor quality.63
HIV infection is not a contraindication to IUD use. The use of an IUD in the context of HIV 
infection is classified according to CDC US medical eligibility criteria for contraceptive use 
as category 2, meaning that HIV is a condition for which the advantages of using the IUD 
generally outweigh theoretical or proven risks.1, 35 However, the use of an IUD by an 
individual with advanced HIV disease is classified as category 3, meaning that risks 
generally outweigh benefits, including the theoretical risk of infection with IUD insertion. 
Therefore, such women should use an alternative contraceptive method other than an IUD 
until their immunologic and clinical status improves with cART. For women with an IUD 
already in place who progress to advanced HIV disease, the IUD can remain in place. 
However, these women may be at increased risk of pelvic infection.35, 53
IUD use did not adversely affect HIV disease progression when compared with hormonal 
contraceptive use and was not associated with increased risk of HIV transmission to 
partners.35 Several small studies have found that levonorgestrel IUDs were not associated 
with increased genital shedding of HIV.64, 65 Limited data also suggest that the efficacy of 
the levonorgestrel IUD is unlikely to be affected by antiretroviral therapy.64, 66 Furthermore, 
evidence suggests that there is no higher risk of overall or infectious complications in HIV-
infected compared with uninfected women.65, 67, 68
Progestin-Only Injectable Contraception
Depot medroxyprogesterone acetate (DMPA), known by the brand name Depo-Provera 
(Pfizer, New York, NY), is progestin given as a single injection approximately every 13 
weeks (up to 15 weeks) with the use of a dose of either 150 mg delivered intramuscularly or 
104 mg delivered subcutaneously.1 This contraceptive method is highly effective at 
preventing pregnancy, with a 1-year probability of pregnancy of approximately 6% for 
typical use and 0.2% with perfect use.1 Similar to the LARC methods, DMPA can be 
administered to those with contraindications to estrogens and is convenient for many 
adolescents; however, it requires injections approximately every 13 weeks. Its main side 
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effects are weight gain, a delayed return to fertility, menstrual bleeding irregularities, and 
bone mineral loss, which is largely reversible after DMPA discontinuation.1, 69, 70
Patients receiving DMPA injections should be counseled about age-appropriate 
recommendations for supplementation with calcium and vitamin D and regular weight- 
bearing exercise as well as avoidance of smoking and alcohol to maintain skeletal health.1 
Some providers obtain dual-energy radiograph absorptiometry scans in adolescent patients at 
baseline when they begin DMPA injections. However, there is no evidence to recommend 
this practice; moreover, initial bone mineral density losses stabilize by 5 years, with return to 
pre-use levels on discontinuation of progestin injections.55 Given the uncertainty 
surrounding the interaction between progestin-only injectables (particularly DMPA) and the 
risk of HIV transmission to male partners,35, 53, 67, 71 as will be discussed later, women with 
HIV infection need to be informed that progestin-only injectables may or may not increase 
their risk of HIV transmission to partners. There is insufficient evidence to confirm any risk 
of disease progression72; however, further research is warranted. Women and couples at high 
risk of HIV who are considering progestin-only injectables should also be informed about 
and have access to HIV-preventive measures, including male and female condoms.53 Levels 
of DMPA do not appear to be reduced by the use of antiretroviral agents (including 
efavirenz, zidovudine, lamivudine, nevirapine, and nelfinavir)73–75; indeed, this agent is 
largely free of antiretroviral interactions and can be administered with all classes of 
antiretroviral agents. Although both HIV disease and the antiretroviral agen tenofovir 
disoproxil fumarate can cause decreases in bone mineral density,76 the effects of 
concomitant use of DMPA and tenofovir disoproxil fumarate on adolescent bone health are 
not known.
Combined Oral Contraceptives
Combined oral contraceptives (COCs) contain an estrogen and a progestin and are available 
by prescription. They are the most commonly used method of hormonal contraception 
among adolescents in the United States1 and are the prototype of other combined methods of 
birth control, such as the vaginal ring and transdermal patch, which have similar efficacy and 
clinical profiles. In almost every pill, the estrogen component is ethinyl estradiol in varying 
amounts, with the “low dose” pill (30–35 μg) being the first line for adolescents.1 Their 
typical- use failure rates are 9% in adults and may be higher in adolescents,1, 77 because they 
depend on user adherence. Approaches to increase adherence include support from a family 
member, friend, or partner or cell phone alarms1 and should include instructions if 1 or more 
pills are missed. As with all estrogen-containing contraceptive methods, COCs have some 
contraindications1, 35; however, most of these are uncommon in the adolescent. Interactions 
with several classes of medications, including some antiretroviral agents,1, 35, 51, 52 are one 
of the main factors limiting the use of COCs in HIV-infected women. Such interactions lead 
mainly to a decrease in contraceptive hormonal levels, potentially leading to decreased 
contraceptive effectiveness, and will be summarized in a later section. A decrease in 
contraceptive effectiveness of COCs is observed particularly with concurrent administration 
of a ritonavir-boosted PI; an alternative or additional contraceptive method should be 
considered when any boosted PI regimen is used. Because nevirapine and efavirenz induce 
the metabolism of COCs and reduce hormonal levels, an alternative or additional 
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contraceptive method should also be considered in women who are taking these 
antiretroviral agents; however, other nonnucleoside reverse transcriptase inhibitors 
(NNRTIs), such as etravirine and rilpivirine, do not seem to cause the same reduction.38 
COCs do not have any significant interactions with nucleoside reverse transcriptase 
inhibitors, integrase inhibitors such as raltegravir and dolutegravir, entry inhibitors such as 
maraviroc, or fusion inhibitors such as enfuvirtide. Preliminary data suggest that 
elvitegravir/cobicistat may alter hormonal concentrations; the clinical significance of this 
finding is not fully known, but COCs with greater than 30μg ethinyl estradiol or alternative 
contraceptives may need to be considered.51
Most of the available evidence has found no statistically significant association between the 
use of COCs and HIV acquisition, HIV transmission to partners, or HIV disease 
progression; however, the quality of the available evidence is generally considered low.
53, 72, 78, 79
Contraceptive Vaginal Ring, Transdermal Contraceptive Patch
These methods have efficacy, benefits, side effects, and drug interactions comparable to 
other combined hormonal methods but represent simpler regimens. Despite the simplified 
regimen afforded by these methods (weekly for the patch and monthly for the vaginal ring), 
studies suggest variable rates of acceptability and low long-term continuation rates among 
adolescents.78, 80, 81 For HIV-infected adolescents, drug interaction considerations are 
similar to those of COCs mentioned previously.35, 52 As with other hormonal methods, a 
condom should always be used concurrently for STI/HIV protection.
Progestin-Only Pills
Progestin-only pills are not typically recommended as a first-choice method in adolescents, 
because they require particular timing of pill administration relative to coitus.1 In addition, 
they are less effective than other progestin-only methods, including the progestin-containing 
IUD, implant, and injectables.1 There is currently no available information regarding the risk 
of HIV acquisition or transmission to partners with the use of progestin-only pills. On the 
basis of limited data, progestin levels with progestin-only pills do not appear to be reduced 
by some PIs,82 but contraceptive efficacy data are not available. Data on hormonal levels 
when progestin-only pills are used with other antiretroviral agents, such as efavirenz or 
nevirapine, are not available.47 Recommendations for use with antiretroviral drugs are 
generally the same as those for COCs discussed previously.35, 51
Male Condoms
Male condoms are the preferred method of barrier contraception because of their 
demonstrated ability to decrease the transmission of STIs, including HIV.1, 79 In addition, 
they are the most common contraceptive method used by adolescents.83 They need to be 
used correctly and consistently with each act of sexual intercourse; therefore, their typical-
use failure rate is 18% for all users and can be higher among adolescents, in contrast to a 
perfect-use failure rate of 2%.84 Latex condoms should only be used with water-based 
lubricants85; natural membrane condoms do not provide adequate STI protection.79 The high 
typical-use failure rate for pregnancy prevention, but added protection from STIs, has led to 
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the recommendation for dual contraception with a condom plus a highly effective hormonal 
or other long-acting contraceptive method.79 More information on condoms can be found in 
the AAP policy statement on condom use by adolescents.79 HIV-infected adolescents should 
always use a condom to prevent HIV transmission to partners.
Emergency Contraception
Several products are available for emergency contraception in the United States, including a 
progestin-only dedicated emergency contraception product (levonorgestrel-based pill), high-
dose combined estrogen-progestin pills, ulipristal acetate (a progesterone receptor 
modulator), and the copper IUD.1 All of these methods can prevent pregnancy when 
initiated up to 5 days after an act of unprotected sexual intercourse but are more effective the 
earlier they are used. More information on emergency contraception can be found in the 
AAP policy statement on emergency contraception.86 Plan B One-Step (levonorgestrel) is 
approved by the Food and Drug Administration as a nonprescription product for all women 
of childbearing potential,87 and generic versions are approved as nonprescription products 
for adolescent females and women aged ≥17 years, even though proof of age is not required 
for purchase.1 Counseling and advance provision of emergency contraception should be a 
part of anticipatory guidance for adolescents.1 Recommendations are not different for HIV-
infected adolescents; however, drug interactions with antiretroviral agents may need to be 
considered. Limited evidence suggests that levonorgestrel levels are significantly reduced 
among women using levonorgestrel emergency contraception who are receiving efavirenz, 
but no efficacy data are available.44 Data for interactions of other types of emergency 
contraception and other antiretroviral agents are not available.47 However, ulipristal acetate 
is predominantly metabolized by CYP3A4, so interactions can be expected.51, 52 The 
efficacy of the copper IUD is not affected by antiretroviral agents.
Spermicides, Diaphragm, Cervical Cap
HIV infection is a contraindication to the use of spermicides, because there is an increased 
risk of genital lesions and resulting viral shedding and transmission of HIV associated with 
nonoxynol-9.35, 88 Diaphragms and cervical caps are contraindicated in HIV-infected 
individuals for similar reasons, mainly because of concerns about the spermicide.89
Fertility Awareness and Other Periodic Abstinence Methods
Although strict abstinence is obviously an effective means of birth control, it is not a realistic 
option for adolescents after their sexual debut. Fertility awareness and other periodic 
abstinence methods are not recommended for adolescents, because they have high failure 
rates.1 A condom should always be used by HIV-infected adolescents to prevent the 
transmission of HIV infection to partners.
Withdrawal
This method has a high contraceptive failure rate,1 and it provides no STI/HIV protection; 
therefore, it is not recommended as a contraceptive method.
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HORMONAL CONTRACEPTION AND HIV RISK
Concerns have been raised about the effects of hormonal contraception on the risk of HIV 
acquisition, the risk of HIV transmission from female to male partners, and HIV disease 
progression. Some observational studies have documented an increased risk of HIV 
acquisition, transmission, and disease progression associated with changes in the genital 
tract during contraceptive use.90–94 Most relevant to this clinical report are the possible 
associations of hormonal contraception with the risk of HIV transmission to partners and 
with HIV disease progression. A secondary analysis from 2 longitudinal studies of HIV 
incidence that followed serodiscordant couples in Africa reported that DMPA use increased 
the risk of HIV transmission from infected women to their male partners.95 Among 
serodiscordant couples in which the HIV-negative partner was male, the rates of HIV 
transmission were 2.61 per 100 person-years when women used hormonal contraception and 
1.51 per 100 person-years when women did not use hormonal contraception (P = .02). This 
study was subject to confounding, because it was not designed to examine HIV risk with 
hormonal contraception and only a small proportion of women used hormonal 
contraceptives (11% of total person-years of follow-up).
In addition, these women were not receiving antiretroviral therapy. Indirect evidence on the 
risk of HIV transmission from female to male partners from 11 studies that assessed genital 
HIV shedding is mixed.96 Studies have reported an association between hormonal 
contraceptive use and increased frequency of shedding of HIV DNA, but not RNA, in the 
genital tract,94, 97–99 although this finding has not been consistently documented in all 
studies.93, 96 Most studies were cross- sectional, had small sample sizes, and evaluated 
different markers of transmissibility (HIV DNA versus RNA). Their results are thus difficult 
to compare or generalize.
Evidence on the effects of hormonal contraception on HIV disease progression was 
reviewed.72 Ten cohort studies consistently found no association with hormonal 
contraceptive use and HIV disease progression compared with nonuse of hormonal 
contraceptives. One randomized controlled trial found that hormonal contraceptive use was 
associated with an increased risk of HIV disease progression compared with copper IUD 
use, but this study had important methodologic shortcomings.72 Thus, the preponderance of 
evidence suggests that HIV-infected women can use hormonal contraceptive methods 
without concerns for HIV disease progression.72
A recent WHO100 consultation concluded that there was, as yet, insufficient evidence to 
support a change in current guidelines on the use of hormonal contraceptives for women 
living with HIV or those at high risk of HIV infection.100 The CDC supports this guidance 
and has added clarification that strongly encourages condom use and other measures to 
prevent HIV infection for at-risk women.35 The WHO encouraged further investigation of 
the relationship of hormonal contraception and HIV risk. Because most of the available 
information on HIV risk derives from studies on women who used DMPA or COCs, very 
limited or no information is currently available on HIV risk related to other hormonal 
methods, such as progestin implants or progestin-releasing IUDs.
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INTERACTIONS OF HORMONAL CONTRACEPTION AND ANTIRETROVIRAL 
DRUGS
Hormonal contraceptives are primarily metabolized in the liver by the cytochrome P450 
system. Antiretroviral agents have varying effects on this metabolic pathway; this is the 
main biological reason for the interaction between the 2 drug categories, although other 
metabolic pathways are sometimes involved. Special consideration is necessary for women 
who use some hormonal methods (ie, combined hormonal contraceptive methods, progestin-
only pills, emergency contraceptive pills, or etonogestrel implants) with certain antiretroviral 
regimens (particularly those containing efavirenz and ritonavir- boosted PIs).53 In addition, 
because efavirenz use may be associated with neural tube defects after early fetal exposure, 
women receiving efavirenz should avoid becoming pregnant, and treatment with efavirenz 
should be avoided during the first 8 weeks of pregnancy whenever possible.51
Data on drug interactions between antiretroviral therapy and hormonal contraceptives come 
primarily from drug-label pharmacokinetics and limited clinical studies, and the clinical 
implications of observed alterations in hormonal or antiretroviral levels are not always 
known. In addition, the magnitude of change in drug levels that may reduce contraceptive 
efficacy or increase adverse effects is not completely known; therefore, the quality of 
evidence is deemed low.35, 100 Up-to-date information regarding drug interactions with 
antiretroviral agents can be found within the regularly updated CDC, WHO, and NIH 
guidelines35, 51–53 Because definitive, high-quality studies on pregnancy rates among 
women taking hormonal contraceptives and receiving antiretroviral therapy do not exist, 
dosing recommendations are based on expert opinion.51 The recommendations referred to in 
this clinical report are based on the consensus of the NIH expert panel51 and may be slightly 
different from those of other sources, including the CDC and the WHO.
A summary of the available evidence on interactions with hormonal contraceptives by 
antiretroviral class is presented in Table 1. Interactions with hormonal contraceptives may 
differ among individual antiretroviral agents in each class. In general, nucleoside reverse 
transcriptase inhibitors and entry inhibitors do not appear to have significant interactions 
with hormonal contraceptive methods.51, 53, 101 With regard to NNRTIs, 3 clinical studies, 
including 1 large study, found that the use of nevirapine-containing cART did not increase 
ovulation or pregnancy rates in women taking COCs.102–105 For efavirenz-containing cART, 
a pharmacokinetic study showed consistently significant decreases in contraceptive hormone 
levels in women taking COCs, and a small clinical study showed higher ovulation rates in 
women taking efavirenz-containing cART and COCs.44, 102, 106 The newer NNRTIs, 
etravirine and rilpivirine, do not interact with COCs.101, 107 On the basis of primarily 
pharmacokinetic data, the efficacy of DMPA is likely not affected by NNRTIs. Efavirenz, 
but likely not nevirapine, decreases levonorgestrel levels and may decrease contraceptive 
efficacy in women using levonorgestrel implants45 or levonorgestrel for emergency 
contraception52; data on interactions of efavirenz with etonogestrel implants are even more 
scarce.
As mentioned earlier, pharmacokinetic data suggest decreases in COC hormone levels with 
ritonavir-boosted PIs. For women using ritonavir-boosted PIs who are taking combination 
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hormonal contraceptives (COC pills, patches, or rings) or progestin-only pills, the use of an 
alternative or additional method of contraception is recommended.35, 51, 52 Atazanavir 
increases ethinyl estradiol concentrations by 50% or more, so with unboosted atazanavir, 
COCs with concentrations of ethinyl estradiol less than 30μg are needed.35, 51, 52 On the 
basis of primarily pharmacokinetic data, the effectiveness of DMPA is likely not affected by 
PIs.53 The concomitant use of hormonal contraceptives and preexposure prophylaxis 
regimens has been evaluated in only a few studies; preexposure prophylaxis was shown to be 
efficacious in women using DMPA and in their partners.108 Similarly, concomitant oral 
tenofovir/emtricitabine use was not associated with changes in plasma levonorgestrel 
concentrations among women using a levonorgestrel implant in the first year of use.109
The efficacy of cART does not appear to be affected by the use of hormonal contraceptive 
methods on the basis of limited clinical data.66, 110–114 Very few data are available on 
whether hormonal contraceptive methods and cART taken together lead to worsening of side 
effects of contraceptives or increased antiretroviral toxicity. Pharmacokinetic data suggest 
that COCs, DMPA, and progestin implants are unlikely to have an effect on cART toxicity.90 
Complete information on all contraceptive methods and possible interactions with 
antiretroviral agents can be found in the CDC-issued Medical Eligibility Criteria for 
Contraceptive Use35 and the regularly updated NIH guidance.51
CONCLUSIONS
The use of effective contraception is necessary in sexually active HIV-infected adolescents, 
because it prevents unintended pregnancy, promotes family planning, and prevents mother-
to-child transmission of HIV. The promotion of these methods, in conjunction with 
education regarding dual protection use, is important. However, several of the antiretroviral 
drugs used in currently recommended regimens for adults and adolescents in the United 
States52 have interactions with some hormonal contraceptives, which may limit their 
efficacy. The evidence on pharmacologic interactions and their clinical significance is still 
emerging. Interactions of LARCs with antiretroviral agents are particularly important to 
determine, because LARCs are the most effective contraceptive methods. The effect of 
hormonal contraceptives on local cervicovaginal concentrations of antiretroviral drugs 
administered topically or systemically will also need to be studied.110 There is a need for the 
development of long-acting, safe, multipurpose prevention technologies that address 
multiple sexual and reproductive health needs of adolescents and young adults as well as 
decreased user adherence requirements.115 Such proof-of-concept technologies might 
include genitally applied products that can afford antiviral and contraceptive activity and 
have longer duration of action.110
Comprehensive reproductive health counseling and care is an important aspect of care for 
HIV-infected adolescent females. This care includes the capacity to provide appropriate 
contraceptive guidance, delivery, and monitoring. Encouraging abstinence,116 delay of 
sexual initiation, correct and consistent condom use, and adherence to the antiretroviral 
regimen are important strategies to improve adolescents’ health, prevent unintended 
pregnancies, and prevent HIV transmission to partners. Clinics and physician practices 
providing primary care for HIV-infected female adolescents need to include comprehensive 
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reproductive health counseling and care and have the capability to provide appropriate 
contraceptive guidance, delivery, and monitoring. Addressing adolescent reproductive health 
issues in the medical home and during routine visits, where family planning services are 
integrated into care, along with antiretroviral therapy adherence and risk-reduction 
counseling, may be one of the best ways to address the sexual and reproductive health needs 
of HIV-infected adolescents.
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ABBREVIATIONS
AAP American Academy of Pediatrics
cART combination antiretroviral therapy
CDC Centers for Disease Control and Prevention
COC combined oral contraceptive
DMPA depot medroxyprogester-one acetate
IUD intrauterine device
LARC long-acting reversible contraceptive
NIH National Institutes of Health
NNRTI nonnucleoside reverse transcriptase inhibitor
PI protease inhibitor
STI sexually transmitted infection
WHO World Health Organization
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